Kornimate/medical-research-clean huggingface dataset:
improving advance care planning by preparing diverse seniors for decision making

Conditions: Chronic Disease

Summary: the objective of this proposal is to test whether a multi-media website (www.prepareforyourcare.org) that is focused on preparing older adults for communication and medical decision making can help people engage in advance care planning.

prepare is a website (www.prepareforyourcare.org) that teaches patients how to identify what is most important in life, how to communicate their preferences to clinicians and loved ones, and how to make informed decisions. it is written at a 5th grade level and includes voice-overs of text and closed captioning of videos that model advance care planning behaviors. the goal of this proposal is to test the efficacy of prepare plus an easy-to-read advance directive, versus an advance directive alone, to improve patient engagement in multiple advance care planning behaviors including discussions with surrogate decision makers and clinicians in addition to advance directive completion. the investigators will also determine whether prepare can empower and activate patients within clinical encounters with their clinicians and help to decrease health disparities in advance care planning.

Eligibility criteria:
inclusion criteria: * english-speaking older adults (≥55 years) * ≥ 2 chronic illnesses determined by international classification of diseases-9 (icd-9) codes * ≥ 2 visits with an outpatient primary care clinician at san francisco general hospital in the past year * ≥2 additional outpatient/inpatient visits to san francisco general hospital in the past year exclusion criteria: * deaf, blind, or demented as determined by icd-9 codes * too mentally or physically ill to participate as determined by their clinicians * moderate or severe cognitive impairment as determined by the short portable mental status questionnaire (spmsq), and mild cognitive impairment as determined by the spmsq plus an abnormal mini-cog * self-reported poor vision and inability to see the words on a newspaper * lack of a telephone * traveling or moving out of the area for ≥3 months during the study follow- up period

Keywords: advance care planning aging health communication health literacy medical decision making primary care vulnerable population chronic illness
weekly topotecan therapy in patients with ovarian cancer

Conditions: Ovarian Cancer

Summary: the purpose of this study is to find out the safety and feasibility of weekly topotecan consolidation therapy in patients with ovarian cancer.

patients with stage iiic and iv optimally-debulked ovarian cancer will be treated with 6 cycles (every 3 weeks) of carboplatin (auc 5) and paclitaxel (175 mg/m2). patients who demonstrate a complete clinical response to this regimen will then be treated with topotecan consolidation (4 mg/m2 weekly x 8 weeks for one cycle followed by a break in the 9th week) for a maximum of 3 cycles. primary endpoints will be toxicity and the determination of the appropriate dose, schedule, and duration of topotecan for further consolidation trials.

Eligibility criteria:
inclusion criteria: * patients must have a histopathologic diagnosis of epithelial ovarian cancer. * patients must have completed front-line chemotherapy and be clinically ned (ca 125 \<35, negative ct scan, negative physical exam). * patients may have a second look laparoscopy, however, there must be no gross disease present (microscopic disease or pathologically negative). * patients must not have had other myelosuppressive therapy within four weeks of initiating topotecan therapy. * topotecan treatment must begin within 10 weeks following last cycle of initial chemotherapy. * patients may have had only one prior chemotherapy regimen. exclusion criteria: * patients with a concomitant malignancy other than squamous cell or basal cell skin cancer. * patients who are pregnant or breast-feeding.

Keywords: ovarian cancer cancer of the ovary
efficacy of topical tranexamic acid in reducing blood loss during cs in patients with placenta previa

Conditions: Placenta Previa

Summary: objectives: to evaluate the efficacy of topical tranexamic acid applied on the placental bed after placental delivery to reduce blood loss during cesarean delivery in women with placenta previa. patients will be randomly assigned into two groups: group (a) - study group (n=28): the topical tranexamic acid group will receive topical tranexamic acid after placental delivery applied on the placental bed for 5 minutes by using a sterile towel soaked with 2g tranexamic acid (kapron, amoun, cairo, egypt) (4 ampules 500ug) diluted in 100ml of sodium chloride 0.9%, in addition to the iv infusion of 1g tranexamic acid (2 ampules 500ug) diluted with 20ml of 5% glucose administered just after delivery of the fetus. group (b) - control group (n=28): the intravenous tranexamic acid group will receive only an iv infusion of 1g of tranexamic acid (2 ampules 500ug) diluted with 20 ml of 5% glucose administered just after delivery of the fetus.


Eligibility criteria:
inclusion criteria: * age: 20-40 years old. * bmi less than 30 kg/m2. * pregnancy of singleton living fetus. * placenta previa by ultrasound assessment * gestational age \> 36 weeks. exclusion criteria: * women with a history of any medical disorder with pregnancy, e.g., gestational diabetes and hypertension. * women with systemic diseases, e.g., diabetes mellites, systemic immune disorders such as systemic lupus erythematosus * women with bleeding tendency or coagulopathy. * women on anticoagulants or hemodynamically unstable women. * women with uterine abnormalities, such as fibroids or polyps. * emergency termination of pregnancy. * intrauterine fetal death. * pregnancy with obstetric hemorrhage, e.g., antepartum hemorrhage * cases of placenta accrete spectrum disorder or placental abruption * women with known allergies to tranexamic acid
french national database of rare dermatological cancers

Conditions: Adnexal Tumor of Skin; Merkel Cell Carcinoma; Advanced Basal Cell Carcinoma Requiring Systemic Treatment

Summary: merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, and cutaneous adnexal carcinomas are 3 types of rare skin cancers for which much remains unknown in terms of natural behavior, prognosis, treatment and outcomes. caraderm is a french prospective national cohort enrolling patients with either one of these 3 tumor types, whose objectives are : * to provide epidemiological, clinical and socio-economic characteristics of patients * to identify new clinical or epidemiological prognostic factors for these rare cancers * to evaluate the impact of various treatments on outcomes

caraderm is a french national multidisciplinary project which will prospectively enroll from 37 french centers any patient presenting with merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment or cutaneous adnexal carcinoma. a structured and centralized database of clinical monitoring of patients will be established. information captured will include clinical constitutional factors, factors linked to primary carcinoma, factors linked to lymph node involvement, "american joint committee on cancer" (ajcc) stage at inclusion, recurrence patterns, therapeutic interventions (medical, surgical, radiotherapy and palliative strategies) with evaluation of response, date of death, date of latest news.

Eligibility criteria:
inclusion criteria: * patients with histologically confirmed merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, or cutaneous adnexal carcinoma exclusion criteria: * subjects without merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, or cutaneous adnexal carcinoma * patients refusal

Keywords: adnexal cutaneous carcinoma merkel cell carcinoma advanced basal cell carcinoma requiring systemic treatment
role of airway hyperresponsiveness on performance in elite swimmers.

Conditions: Asthma

Summary: the prevalence of airway hyperresponsiveness (ahr) is very high in elite swimmers, reaching 80% in certain studies. repeated chlorine-derivatives exposure may be a major causative factor for its development. asthma diagnosis is generally made on the basis of clinical characteristics. the demonstration of a variable bronchial obstruction through positive expiratory flow reversibility to a bronchodilator, spontaneous variations of airway obstruction or a positive provocation test (methacholine, eucapnic voluntary hyperpnoea...) is necessary to avoid false diagnosis. currently asthma treatment in swimmers is the same as in the general population. a short-acting bronchodilator is often prescribed to avoid occasional symptoms, combined with an inhaled corticosteroid or an antagonist of leukotriene if asthma symptoms are persistent. previous studies have shown a reduced efficiency for asthma medication in elite athletes compared with non-athletes. the specific response to different medications remains to be studied in athletes. the effects of a short-acting bronchodilator in swimmers with ahr, especially when asymptomatic, on pulmonary function and performance have not yet been studied. moreover, the significance of a positive bronchial provocation test remains to be studied in asymptomatic swimmers with ahr.

our hypothesis is that swimmers with a positive bronchial provocation challenge have not necessarily an exercise-induced bronchoconstriction during swimming and the use of a bronchodilator will be unnecessary. chlorine-derivatives exposure may be responsible for a weakness of the epithelium layer but warm and humid atmosphere of the swimming-pools may be protective for the development of a bronchoconstriction. thus we also hypothesis that during a field test outside the swimming pool, swimmers will develop an exercise-induced asthma, and will need to take a bronchodilator in prevention.

Eligibility criteria:
inclusion criteria: * swimmer (at least 10h/week) aged from at least 14 years. exclusion criteria: * smoker, obese or other disease which may interfere with the study. some parts of the study may exclude swimmers taking inhaled corticosteroids.
protectivity and safety of dtp/hb/hib (bio farma) vaccines in infants, batch consistency, multi center trial

Conditions: Healthy

Summary: the objectives of this study were to analyze the immunogenicity and reactogenicity of dtp/hb/hib (bio farma) combination vaccine.

this trial was randomized, double blind, prospective intervention and multi centers. total 600 subject (6-11 weeks of ages) followed this trial, divided into 3 groups, each group consists of 200 subjects. a number of 342 subjects were recruited in bandung, while 258 subjects were recruited in jakarta.

Eligibility criteria:
inclusion criteria: * infant 6-11 week of age * infant born after 37-42 week of pregnancy * infant weighting more than 2.5 kg at birth * father, mother or legally acceptable representative properly informed about the study and having signed the informed consent form * parents commit themselves to comply with the indication of the investigator and with the schedule of the trial * mother at least graduate from elementary school * received hepatitis b vaccine (bio farma) at birth exclusion criteria: * child concomitantly enroll or schedule to be enroll in another trial * evolving moderate or severe illness, especially infectious diseases or fever (axillary temperature \>=37.5 celsius on day 0) * known history of allergy to any component of the vaccine component (e.g.formaldehyde) * history of uncontrolled coagulopathy or blood disorder contraindicating intramuscular injection * known history of congenital or acquired immunodeficiency (including hiv infection) * child who has received in the previous 4 weeks a treatment likely to alter the immune response (intravenous immunoglobulin, blood derived product or long term corticotherapy (\>2 weeks) * other vaccination within the 1 month prior to inclusion with the exception of bcg and poliomyelitis * any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objective * infant with a known history of diphteria, tetanus, pertussis, hib, hepatitis b infection

Keywords: combined pentavalent dtp/hb/hib vaccine infants primary vaccination
comparative genomic profiling of lung adenocarcinoma in asians and caucasians: a propensity matched analysis

Conditions: Adenocarcinoma of Lung

Summary: lung adenocarcinomas (luads) from asian ancestry are reported to have different genomic architectures compared with luads from caucasian ancestry. however, due to lack of available cases, few studies controlled the clinical attributes during the comparisons of the genomic alterations. in this study, the investigators will identify asian luads patients who had broad-panel next-generation sequencing (ngs) performed on their primary tumor between january 2018 and december 2019 at the department of thoracic surgery of peking university people's hospital. then, caucasian luads patients who had targeted ngs (memorial sloan kettering-integrated mutation profiling of actionable cancer targets \[msk-impact\]) will be identified in the genie database, which consists of 6673 primary lung adenocarcinoma samples with clinical annotations. finally, genomic alterations regarding somatic mutations, copy number variations, fusions, mutational signatures, oncogenic pathways, and therapeutic actionability will be comprehensively compared between these two cohorts after adjusting age, sex, smoking status, and pathologic stage using propensity score matching. this study will elucidate important ancestry differences between asian and caucasian lung adenocarcinoma patients.


Eligibility criteria:
inclusion criteria: * primary lung adenocarcinoma * broad-panel next-generation sequencing * asian exclusion criteria: * inadequate clinicopathological information * low-quality next-generation sequencing

Keywords: lung adenocarcinoma next-generation sequencing tumor genomic profiling ethnic differences
zanubrutinib, obinutuzumab and lenalidomide (zgr) in high-risk treatment-naive patients with follicular lymphoma (fl)

Conditions: Follicular Lymphoma

Summary: this is a prospective, multiple-centers, open-label, single-arm clinical study designed to evaluate the efficacy and safety of zanubrutinib, obinutuzumab, and lenalidomide (zgr) in high-risk treatment-naive patients with follicular lymphomas


Eligibility criteria:
inclusion criteria: 1. pathologically confirmed cd20 positive follicular lymphoma grade 1, 2, or 3a based on 2016 who classification 2. treatment naive 3. age ≥ 18 years 4. indications for treatment confirmed 5. identified as high-risk group by follicular lymphoma international prognostic index 2 (flipi2) at enrollment 6. must has measurable lesion in ct or pet-ct prior to treatment 7. considered suitable for zgr regimens 8. informed consented exclusion criteria: * transformed follicular lymphoma or 3b follicular lymphoma; * hbsag positive and / or hbcab positive with hbv dna titer; hcv antibody positive with hcv-rna; or hiv positive * any drug contraindication in the treatment plan * pregnant or lactating women * patients judged by other researchers to be unsuitable for inclusion in the study

Keywords: zanubrutinib lymphoma
effect of alirocumab (sar236553/regn727) administered on top of ezetimibe or fenofibrate on lipid profiles in healthy subjects

Conditions: Hypercholesterolemia

Summary: primary objective: to assess the pharmacodynamic profile of alirocumab (sar236553/regn727) administered either alone or on top of ezetimibe or fenofibrate, based on low-density lipoprotein -cholesterol (ldl-c). secondary objectives: * to assess the pharmacodynamic profile of alirocumab administered either alone or on top of ezetimibe or fenofibrate, based on other lipid parameters. * to assess the pharmacokinetic profile of alirocumab administered either alone or on top of ezetimibe or fenofibrate.

total duration of the study per subject (excluding screening) is about 22 weeks.

Eligibility criteria:
inclusion criteria : * healthy male /or female subjects, * aged 18 to 65 years old, * with ldl-c \> 130 mg/dl * not receiving lipid lowering therapy. exclusion criteria: * healthy subjects with history or presence of clinically relevant illness. * subjects currently taking statins, ezetimibe or fenofibrate. * the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
the outcomes of hypertension in obese versus non-obese pregnant women

Conditions: Hypertension in Pregnancy

Summary: hypertensive disorders of pregnancy, include pre-existing and gestational hypertension, preeclampsia, and eclampsia, it complicates up to 10% of pregnancies and represents a significant cause of maternal and perinatal morbidity and mortality. following the "national high blood pressure education program working group on high blood pressure in pregnancy" recommendation is currently a systolic blood pressure (sbp) ⩾ of 140 mmhg and diastolic blood pressure (dbp) ⩾ of 90 mmhg. the diagnosis generally requires two separate measurements. accepted across international guidelines are the following four categories: chronic/pre-existing hypertension (hypertension discovered preconception or prior to 20 weeks gestation), gestational hypertension (hypertension that appears de novo after 20 weeks gestation and normalizes after pregnancy), preeclampsia-eclampsia (de novo hypertension after 20 weeks' gestation accompanied by proteinuria, other features of maternal organ dysfunction or uteroplacental dysfunction), chronic/pre-existing hypertension with superimposed preeclampsia-eclampsia. over the past 2 decades, extensive epidemiologic studies have clearly established that obesity is a major risk for gestational hypertension and preeclampsia. the risk of preeclampsia typically doubles with each 5-7 kg/m2 increase in pre-pregnancy. the mechanisms have only been partially explored; increased cytokine-mediated inflammation and oxidative stress, increased shear stress, dyslipidemia, and increased sympathetic activity1 have all been proposed as possible pathways. few studies have examined the relationship between pre-pregnancy bmi, gestational weight gain (gwg), and the risk of preeclampsia. so, our study aims to evaluate the adverse maternal and fetal outcomes related to hypertension in obese and non-obese pregnant women.


Eligibility criteria:
inclusion criteria: 1. women aged from 20-35 years. 2. pregnant women from 28-30 weeks. 3. pregnant women with a singleton pregnancy. 4. women with chronic or gestational hypertension. 5. women with normal baseline investigations (uncomplicated hypertension). 6. obese women and non-obese women. exclusion criteria: 1. women with preeclampsia/eclampsia. 2. women need urgent termination of pregnancy. 3. women with co-morbidities such as diabetes, renal diseases, cardiac ...etc. 4. women with confirmed fetal malformation. 5. women who will refuse to participate.
lapatinib and bevacizumab for metastatic breast cancer

Conditions: Neoplasms, Breast

Summary: this study will examine the efficacy and safety of lapatinib and bevacizumab in patients with erbb2-overexpressing breast cancer.


Eligibility criteria:
inclusion criteria: * females that are at least 18 years of age. * women of childbearing potential must have a negative serum pregnancy test at screening. * documented evidence of her2-overexpressing unresectable or metastatic breast cancer. disease may/may not have been treated in metastatic setting. * subjects are permitted (but not required) to have previously-treated brain metastases that are stable and asymptomatic. * adequate hepatic, renal and cardiac function * ecog score 0-1 and a life expectancy of at least 12 weeks. * able to swallow oral medication * signed informed consent exclusion criteria: * pregnancy * unstable or symptomatic cns metastases * major surgery within 28 days of enrollment (minor surgery within 7 days). * prior anti-cancer treatment within 14 days of enrollment, or unresolved treatment-related toxicities. * a serious non-healing wound, ulcer, or bone fracture at baseline. * class ii, iii or iv heart failure as defined by the nyha functional classification system * history of significant vascular disease, arterial thrombosis, unstable inr, hypertensive crisis, or uncontrolled hypertension. * history of myocardial infarction, stenting procedure, or angioplasty within 6 months of enrollment. * history of abdominal fistulae, gastrointestinal perforation, or intra-abdominal abscess within 6 months of enrollment. * history of malabsorption syndrome, ulcerative colitis, or bowel obstruction. * proteinuria * requires concurrent anti-cancer treatment or investigational treatment. * known hypersensitivity to either study medication * received investigational treatment within 28 days or 5 half-lives, whichever is longer * concurrent disease or circumstances that would lead the investigator would consider the subject an inappropriate candidate for the study * requires medication that has been excluded during study participation

Keywords: vegf tyrosine kinase erbb2 her2-neu metastatic breast cancer egfr erbb1 bevacizumab lapatinib breast carcinoma breast cancer breast lump breast cancer positive for human epidermal growth factor receptor 2 (her2) her2 positive metastatic breast cancer breast cancer progression estrogen-receptor (er) positive(+) breast cancer paget's disease
post-operative analgesia in elective, soft-tissue hand surgery

Conditions: Carpal Tunnel; Ganglion Cyst; Trigger Finger; De Quervain Disease

Summary: the purpose of this research study is to find out which combination of pain medications following surgery work the best and result in the fewest side effects.

this is a prospective, randomized, double-blind study comparing the efficacy of acetaminophen/hydrocodone (ah) to acetaminophen/ibuprofen (aibu) in providing adequate post-operative pain relief in elective, soft tissue hand surgery patients.

Eligibility criteria:
inclusion criteria: * age greater than or equal to 18 * male or female (non-pregnant) * elective, soft tissue hand surgery indicated based on diagnosis made by either clinical exam or diagnostic studies (ie nerve conduction study, emg) or a combination of the two (carpal tunnel release, trigger finger release, first dorsal compartment release, ganglion cyst excision, second extensor compartment release) * subjects are capable of giving informed consent exclusion criteria: * allergy to study medication * any pre-existing pain condition requiring analgesia * fibromyalgia * recent upper gastrointestinal bleeding * coagulopathy (primary or medication-related) * renal impairment * liver disease * pregnancy * patients who consent to the study but require unexpected admission, including those requiring admission resulting from operative complications, will be excluded before randomization

Keywords: adult soft-tissue hand surgery